Kane Biotech (TSXV:KNE) FCF Margin % : -42.56% (As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kane Biotech's Free Cash Flow for the three months ended in Sep. 2024 was C$-0.55 Mil. Kane Biotech's Revenue for the three months ended in Sep. 2024 was C$1.28 Mil. Therefore, Kane Biotech's FCF Margin % for the quarter that ended in Sep. 2024 was -42.56%.

As of today, Kane Biotech's current FCF Yield % is -29.99%.

The historical rank and industry rank for Kane Biotech's FCF Margin % or its related term are showing as below:

TSXV:KNE' s FCF Margin % Range Over the Past 10 Years
Min: -2942.86 Med: -638.41 Max: -57.97
Current: -225.38

During the past 13 years, the highest FCF Margin % of Kane Biotech was -57.97%. The lowest was -2942.86%. And the median was -638.41%.

TSXV:KNE's FCF Margin % is ranked worse than
56.27% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs TSXV:KNE: -225.38

Kane Biotech FCF Margin % Historical Data

The historical data trend for Kane Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech FCF Margin % Chart

Kane Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-57.97

-302.91

-164.37

-1,989.81

-1,430.87

Kane Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-2,744.44	-1,375.86	-1,905.77	-355.16	-42.56

Competitive Comparison of Kane Biotech's FCF Margin %

For the Biotechnology subindustry, Kane Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kane Biotech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kane Biotech's FCF Margin % falls into.

Kane Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kane Biotech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.132	/	0.149
	=	-1,430.87 %

Kane Biotech's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.546	/	1.283
	=	-42.56 %

Kane Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kane Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kane Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

KNBIF:USA

Address

290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2

Website

https://www.kanebiotech.com

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.

Executives

Marc Edwards	Director
Philip Renaud	Director
Raymond David Eugene Dupuis	Senior Officer
Richard J. Renaud	10% Security Holder
Georges Morin	Director
Rashieda Gluck	Director

Kane Biotech Headlines

No Headlines